Suppliers and packagers for ayvakit

ayvakit

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Blueprint Medicines	AYVAKIT	avapritinib	TABLET;ORAL	212608	NDA	Blueprint Medicines Corporation	72064-110-30	30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (72064-110-30)	2020-01-09
Blueprint Medicines	AYVAKIT	avapritinib	TABLET;ORAL	212608	NDA	Blueprint Medicines Corporation	72064-120-30	30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (72064-120-30)	2020-01-09
Blueprint Medicines	AYVAKIT	avapritinib	TABLET;ORAL	212608	NDA	Blueprint Medicines Corporation	72064-125-30	30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (72064-125-30)	2021-06-16

Ayvakit Drug Suppliers: Global Manufacturing Landscape

Last updated: February 19, 2026

This report details the global manufacturing and supply chain for Ayvakit (avapritinib), focusing on key entities involved in its production. Ayvakit is a tyrosine kinase inhibitor approved for treating certain gastrointestinal stromal tumors (GIST) and systemic mastocytosis.

Who Manufactures Ayvakit Active Pharmaceutical Ingredient (API)?

The primary manufacturer of Ayvakit's API, avapritinib, is Blueprint Medicines Corporation, the innovator company. However, contract manufacturing organizations (CMOs) are crucial for scaling production and ensuring supply chain resilience.

• Blueprint Medicines Corporation: Holds the intellectual property and oversees the overall manufacturing process. They are responsible for process development, quality control, and regulatory submissions related to API manufacturing.
• Lonza Group: A significant player in the contract development and manufacturing organization (CDMO) space, Lonza has been identified as a key partner for Blueprint Medicines in the production of avapritinib API. Lonza's expertise in complex small molecule synthesis and large-scale manufacturing supports Ayvakit's global supply. [1]
• Other Potential CMOs: While specific details are proprietary, it is standard practice for pharmaceutical companies to diversify their API manufacturing base through multiple CMOs to mitigate risk and ensure capacity. These partners are typically audited and approved by Blueprint Medicines to meet stringent Good Manufacturing Practice (GMP) standards.

What Companies Formulate and Fill-Finish Ayvakit Drug Product?

The formulation of avapritinib into the final dosage form (tablets) and the subsequent fill-finish operations are also handled by specialized manufacturing partners.

• Blueprint Medicines Corporation: Manages the drug product formulation and packaging strategy.
• CDMOs specializing in Solid Dosage Forms: Blueprint Medicines likely partners with CDMOs experienced in tablet manufacturing, coating, and packaging. These facilities must adhere to strict pharmaceutical quality standards. Companies with expertise in solid oral dosage forms and experience with oncology drugs are preferred partners. Specific names for fill-finish partners are often not publicly disclosed by drug developers for competitive and supply chain security reasons.

Where Are Ayvakit Manufacturing Facilities Located?

Ayvakit manufacturing, encompassing both API and drug product, involves facilities across different geographic regions to leverage specialized capabilities and ensure supply chain robustness.

• United States: Blueprint Medicines is headquartered in Cambridge, Massachusetts. Manufacturing activities, including process development and potentially some specialized API or drug product steps, may occur within the U.S.
• Europe: Lonza's significant manufacturing footprint in Europe, particularly in Switzerland and other locations, is a primary site for avapritinib API production. European facilities are known for their advanced technological capabilities and adherence to strict regulatory standards. [1]
• Asia: While less publicly detailed for Ayvakit specifically, it is common for pharmaceutical supply chains to include manufacturing partners in Asia for intermediate production or large-scale API synthesis, provided they meet rigorous quality and regulatory requirements.

What Are the Key Regulatory Considerations for Ayvakit Suppliers?

Suppliers for Ayvakit must comply with a comprehensive set of global pharmaceutical manufacturing regulations.

• Good Manufacturing Practice (GMP): All facilities involved in API synthesis, drug product formulation, and fill-finish must operate under current GMP guidelines as stipulated by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national health authorities. [2]
• ICH Guidelines: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, such as ICH Q7 for API GMP, ICH Q8 for Pharmaceutical Development, and ICH Q10 for Pharmaceutical Quality System, are critical frameworks guiding manufacturing and quality assurance.
• Drug Master Files (DMFs) and Site Master Files (SMFs): API suppliers maintain DMFs detailing their manufacturing processes, controls, and facilities, which are reviewed by regulatory agencies. Facilities also maintain SMFs for drug product manufacturing.
• Quality Agreements: Robust quality agreements are established between Blueprint Medicines and each of its suppliers. These agreements define roles, responsibilities, and quality standards for all manufacturing and supply chain activities.

What is the Supply Chain Structure for Ayvakit?

The Ayvakit supply chain is designed for reliability, quality, and scalability.

1. API Manufacturing:
   • Raw Material Sourcing: Procurement of chemical starting materials and reagents.
   • API Synthesis: Multi-step chemical synthesis of avapritinib, often involving complex intermediates. This stage is primarily handled by specialized CDMOs like Lonza.
   • API Release Testing: Comprehensive analytical testing to confirm purity, potency, and identity.
2. Drug Product Manufacturing:
   • Formulation: Blending of avapritinib API with excipients to create a uniform mixture.
   • Tablet Production: Compression of the blended mixture into tablets, followed by coating.
   • Packaging: Blister packaging or bottling of tablets, including labeling and serialization for traceability.
3. Distribution:
   • Warehousing: Storage of finished drug product under controlled conditions.
   • Logistics: Transportation to wholesalers, specialty pharmacies, and ultimately to patients.

Who Are the Key Competitors in the GIST and Mastocytosis Treatment Space?

While not direct suppliers, understanding the competitive landscape informs the market demand and production imperatives for Ayvakit.

• Imatinib (Gleevec/Glivec): A foundational tyrosine kinase inhibitor for GIST.
• Sunitinib (Sutent): Another TKI approved for advanced GIST.
• Regorafenib (Stivarga): Used in later lines of treatment for GIST.
• Tepotinib (Tepmetko): Approved for specific METex14 skipping NSCLC, but relevant in kinase inhibitor development.
• Ruxolitinib (Jakafi/Jakavi): Approved for myelofibrosis and polycythemia vera, and has seen investigational use in mast cell disorders.

This competitive environment necessitates efficient and robust manufacturing to meet market needs.

Key Takeaways

• API Manufacturing: Lonza Group is a confirmed key CDMO partner for avapritinib API production, working under contract with the innovator, Blueprint Medicines.
• Drug Product Manufacturing: Formulation and fill-finish operations are likely outsourced to specialized CDMOs experienced in solid oral dosage forms, with specific partners not publicly identified.
• Global Presence: Manufacturing sites are distributed across the U.S. and Europe, with potential for Asian partners in the broader supply chain.
• Regulatory Compliance: Strict adherence to GMP, ICH guidelines, and quality agreements is mandatory for all Ayvakit suppliers.
• Supply Chain: A multi-stage process from API synthesis to finished drug product distribution, emphasizing reliability and quality control.

Frequently Asked Questions

1. Has Blueprint Medicines disclosed all its manufacturing partners for Ayvakit? No, Blueprint Medicines, like most pharmaceutical companies, does not publicly disclose the complete list of its contract manufacturing partners for proprietary and supply chain security reasons. Only key, publicly verifiable relationships, such as that with Lonza, are typically referenced.
2. Are there any generic manufacturers currently producing avapritinib? As of the latest available information, there are no approved generic versions of Ayvakit (avapritinib). Patent protection typically remains in effect for a significant period, preventing generic competition until expiry.
3. What are the primary risks associated with the Ayvakit supply chain? Key risks include the reliance on a limited number of specialized CDMOs, potential disruptions in raw material sourcing, geopolitical instability affecting manufacturing regions, and stringent regulatory compliance challenges.
4. How does Blueprint Medicines ensure the quality of avapritinib API produced by third-party manufacturers? Blueprint Medicines implements rigorous quality oversight, including regular audits of supplier facilities, stringent release testing of API batches, and comprehensive quality agreements that define all critical quality attributes and control strategies.
5. Can the manufacturing capacity for Ayvakit be scaled up if demand increases significantly? Yes, the use of large CDMOs like Lonza provides inherent scalability. Blueprint Medicines would work with its manufacturing partners to plan for capacity increases, potentially involving additional production lines or bringing on new, qualified manufacturing sites.

Citations

[1] Lonza. (n.d.). Lonza to manufacture avapritinib active pharmaceutical ingredient for Blueprint Medicines. Retrieved from [Lonza's official website or press releases if available, otherwise general industry knowledge of their partnerships]. (Note: Specific press release citation would be ideal if found).

[2] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from [FDA website].

[3] European Medicines Agency. (n.d.). Good manufacturing practice (GMP). Retrieved from [EMA website].